As April approaches, the global biopharma investment community is zeroing in on a single date: April 10. That’s when the FDA is expected to deliver its verdict on orforglipron, Eli Lilly (LLY)’s highly anticipated oral weight-loss candidate. For a company that briefly touched a $1 trillion market cap in late 2025, the stakes couldn’t be higher—especially with shares now trading roughly 19% below their all-time high.
Eli Lilly’s dominance in the obesity market is well established. With tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for obesity—the company holds roughly 60% of the US market. In the fourth quarter alone, the two drugs combined to generate over $11 billion in revenue, each posting triple-digit growth.
But the injectable stronghold isn’t without vulnerabilities. Patient demand for greater convenience is growing, and competitor Novo Nordisk already launched an oral version of Wegovy in late 2025. While a first mover in the oral category, Novo’s pill comes with trade-offs: it must be taken first thing in the morning on an empty stomach, with food and beverage restrictions.
That’s where orforglipron enters. Lilly’s oral GLP-1 candidate has delivered solid efficacy data in clinical trials, but its real edge may be convenience. Unlike Novo’s offering, orforglipron does not require fasting or fluid restrictions. For Lilly, an oral formulation also brings manufacturing and storage efficiencies, potentially translating into higher margins.
From an investment standpoint, the April 10 FDA decision is likely to be a near-term share-price driver. An approval would open a significant new growth avenue for Lilly, particularly as the weight-loss market is projected to approach $100 billion by the end of the decade.
But the central question dividing investors is whether the market has already priced in the approval.
On one hand, Lilly’s stock has pulled back about 19% from its late-2025 peak of $1,133.95. At roughly 27 times forward earnings, the valuation looks more attractive than it did just a few months ago. On the other hand, concerns over intensifying competition are growing. Novo Nordisk continues to advance its own pipeline, and a host of biotech players are entering the fray—any of which could pressure pricing power and margins over time.
Even if the obesity market matures faster than expected, Lilly is not a one-thesis story.
Unlike Novo Nordisk, which remains heavily reliant on its GLP-1 franchise, Lilly has established growth drivers outside metabolic disease. Its cancer drug Verzenio generated $5.7 billion in sales last year, up 8% year over year. The immunology drug Taltz brought in $3.6 billion, a 9% increase. Meanwhile, Lilly has been steadily building out its pipeline through both internal R&D and licensing deals, with candidates spanning pain management, oncology, and immunology.
This diversification provides a cushion: even if the weight-loss market faces periodic turbulence, Lilly’s broader portfolio offers a foundation for sustained growth.
For long-term investors, the recent pullback hasn’t eroded the core investment case.
Short-term traders, of course, need to weigh the risk of a post-approval sell-off—a classic “buy the rumor, sell the news” scenario. But for those with a longer horizon, trying to time the perfect entry around a single FDA decision date is often a fool’s errand. As Lilly has already demonstrated with Mounjaro and Zepbound, true value creation for a market-leading company tends to play out over years, not days.
Ultimately, if an investor believes in the long-term trajectory of the obesity market and trusts that Lilly’s combination of commercial execution, pipeline depth, and portfolio diversification will sustain its leadership, then the current valuation offers a reasonable entry point—whether that’s before or after April 10. The upcoming FDA decision may serve more as a milestone confirming the next phase of Lilly’s growth story than as a definitive moment to buy or sell.
